EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification
(World News Science)

EMD Serono Announces JAMA Publication of Phase II Results of Sprifermin for Osteoarthritis Structure Modification - Multi-year analysis indicates investigational sprifermin increased cartilage thickness in patients with knee osteoarthritis (OA), compared with placebo in the Phase II FORWARD trial - Dose-dependent structural changes indicate potential of sprifermin to have a structure-modifying effect in OA - Post-hoc, exploratory analysis of the FORWARD trial, to be featured as an oral presentation at the American College of Rheumatology (ACR) Annual Meeting, supports further investigation of sprifermin as a potential disease-modifying OA treatment in a targeted at-risk patient population -...